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Objective: Newborn screening for cystic ﬁbrosis (NBS CF) in Poland is a public
health policy program started in September 2006. Summary from four years’
experience is presented in this study.
Patients and Methods: The IRT/DNA strategy was implemented. DNA analysis
was performed using direct sequencing of selected CFTR regions. The group of
1,212,487 newborns were screened for cystic ﬁbrosis during the programme.
Results: A total of 221 CF cases were identiﬁed during this period. In addition, four
CF cases were reported to be omitted by NBS CF programme. Disease incidence
in Poland based on the programme results was estimated as 1/4394 and carrier
frequency as 1/33. The frequency of the p.Phe508delCTT was similar (62%) to
population data previously reported. This strategy allowed to identiﬁed twenty-nine
affected infants with rare CFTR genotypes. The frequency of some mutations (for
example c.2052_2053insA, p.Lys710X) was assessed in Poland for the ﬁrst time.
Conclusions: Sequencing assay seems to be accurate method for screening pro-
gramme using blood spots in Polish population.
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Background: NBS program was established in Tuscany in 1982. In 2011 DNA
mutation analysis was introduced to improve accuracy, taking into account costs
and genetic background in our region.
Aims: To assess the performance of the NBS protocol in the period 2000–2010.
Methods: We reviewed the NBS data-base. Our three-stage protocol included:
1. an initial immunoreactive trypsin (IRT) measurement (99th centile cut-off −
DelﬁaTM and AutodelﬁaTM);
2. meconium lactase dosage and a second IRT blood sample taken at 4 weeks of
age;
3. the sweat test (ST).
Results: There were 347,815 babies screened in Tuscany in the period 2000–2010.
Of these, 82 were diagnosed with CF and 9 (0.0026%) were known false negative
cases. 12 infants were diagnosed by meconium ileus in this period and 10/12 were
IRT-positive. Incidence of CF was 1 in 3,443 newborns. 12/92 (13%) had borderline
ST at the diagnosis and 2 CFTR mutations. The median (IQR) age at the diagnosis
was 46 (37, 57) days in the last 5-year period compared with 54 (48, 62) days
in the previous years (p< 0.05). Considering the false negative cases, the median
(IQR) age at diagnosis was 0.6 (0.3, 1.4) years; 3/9 had pancreatic insufﬁciency
and respiratory symptoms, 5/9 had only salt loss as clinical features consistent with
CF. Considering the 2006–2010 period, IRT-1 was positive in 0.91%; sensitivity,
speciﬁcity, positive and negative predictive values were 92.98, 99.82, 13.80 and
99.99%, respectively.
Conclusions: Critical points in our program were a relatively late diagnosis age and
the low positive predictive value. An IRT cut-off reassessment and the introduction
of DNA analysis should improve the performance of our program.
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Objective: To present the ﬁrst three year’s experience of NBS for Cystic Fibrosis
(CF) in Ontario.
Methods: Dried blood spot specimens from infants were assayed for immunore-
active trypsinogen (IRT) via radio-immunoassay. Infants with IRT >96 centile had
CFTR mutation analysis using the TM Biosciences Tag-It CFTR 39+3 mutation kit.
Newborn Screening Ontario (NSO) created a categorical system to stratify screen
positive results by risk: Category A: high IRT and two CFTR mutations, high risk
(~100%); Category B: high IRT and one CFTR mutation, moderate risk (~2.5%);
and Category C: elevated IRT above the 99.9 centile and no CFTR mutations, low
risk (~1%). All infants with a screen positive result were referred for follow-up
diagnostic testing at a regional NBS treatment centre.
Approximately 428,762 infants have been screened for CF; of those, 1257 were
screen positive. NSO has identiﬁed 77 conﬁrmed cases of CF. Eight hundred and
seventy-one infants with a Category B screen positive have been conﬁrmed to be
unaffected carriers of CF. A subset of infants with borderline sweat chloride results
(n = 24) are being followed to investigate the possibility of late onset CFTR-related
disease. Follow-up data is pending on 96 infants.
Conclusions: After three years of screening, the screen positive rate for CF in
Ontario is 0.29%. The positive predictive value of the test varies by screen positive
result: 100% for Category A, 4.49% for Category B, and 1.29% for Category C.
Infants with CF identiﬁed through NBS will be followed prospectively to determine
if early detection improves the clinical course of disease.
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Background: There is signiﬁcant variation across the world with respect to the
cut-off for the ﬁrst IRT value (IRT-1) that triggers referral for further testing. In
the UK, infants with an IRT-1 value above the 99.5th centile are referred, whilst
other countries have adopted lower cut-offs (as low as the 95th centile). Taking the
NBS blood spot sample after day 5 of life (as per the UK protocol) may result in
a better differentiation between CF and non-CF, as IRT values in non-CF infants
have been shown to fall in the ﬁrst week of life.
Objective: To examine the performance of the UK protocol since implementation
of NBS in February 2007.
Methods: We recorded
1. IRT-1 for all conﬁrmed CF cases
2. IRT-1 for approximately 8000 consecutive infants in 2011 with a “CF not
suspected” result and
3. IRT-1 for infants recognised as carriers.
Samples were excluded if they were repeats, contaminated, taken before D5 of life
or after week 8. Results were from the NBS laboratory in Liverpool (screens approx
28,000 infants per year).
Results: For 75 infants with a conﬁrmed diagnosis of CF, mean IRT-1 was 164.6
(SD, 82.4, lowest value 66.3). For 25 infants with a carrier result, mean IRT-1 was
81.5 (16.1). For 8052 randomly selected infants with a “CF not suspected” NBS
result, the mean IRT-1 was 22.0 (10.5). There have been no false negatives reported
in this group.
Conclusions: The UK protocol appears to be performing well with a relatively
high IRT-1 cut-off. There is some overlap between “CF conﬁrmed” and “CF not
suspected” IRT-1 values but not signiﬁcant. It appears valid to employ a cut-off of
99.5th centile when the IRT-1 sample is obtained on day 5 of life.
